Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Bristol Myers Squibb (BMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$52.76 | $75.00 | $37.00 | -0.26% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Bristol Myers Squibb comes to $52.76. The forecasts range from a low of $37.00 to a high of $75.00. The average price target represents a decline of 0.26% from the last closing price of $52.90.
Analyst Price Targets (21)
Broker Rating
Bristol Myers Squibb currently has an average brokerage recommendation (ABR) of 2.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.68 a month ago based on 24 recommendations.
Of the 25 recommendations deriving the current ABR, five are Strong Buy, representing 20% of all recommendations. A month ago, Strong Buy made up 20.83%, while Buy represented 4.17%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 |
Buy | 0 | 0 | 1 | 1 | 1 |
Hold | 18 | 18 | 16 | 17 | 17 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 1 | 1 |
ABR | 2.73 | 2.73 | 2.68 | 2.60 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/23/2024 | BMO Capital Markets | Evan Seigerman | Hold | Hold |
9/16/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/28/2024 | Not Identified | Not Identified | Hold | Hold |
8/22/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
8/12/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
8/6/2024 | Berenberg Bank | Luisa Hector | Hold | Hold |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
7/29/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/28/2024 | William Blair | Matt Phipps | Hold | Hold |
7/22/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
7/12/2024 | SVB Securities | David Risinger | Hold | Hold |
7/12/2024 | UBS | Trung Huynh | Hold | Hold |
7/11/2024 | Not Identified | Not Identified | Hold | Hold |
7/11/2024 | Atlantic Equities | Steven K Chesney | Hold | Hold |
5/27/2024 | Not Identified | Not Identified | Hold | Hold |
5/1/2024 | Daiwa America | Narumi Nakagiri | Moderate Buy | Hold |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/18/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
3/27/2024 | Guggenheim Securities | Seamus Fernandez | Hold | Hold |
3/22/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.73 |
ABR (Last week) | 2.73 |
# of Recs in ABR | 25 |
Average Target Price | $52.76 |
LT Growth Rate | 5.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | 1.57 |
BMY FAQs
Bristol Myers Squibb Company (BMY) currently has an average brokerage recommendation (ABR) of 2.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms.
The average price target for Bristol Myers Squibb Company (BMY) is $52.76. The current on short-term price targets is based on 13 reports.
The forecasts for Bristol Myers Squibb Company (BMY) range from a low of $37 to a high of $75. The average price target represents a decline of $1.86 from the last closing price of $53.76.
The current DOWNSIDE for Bristol Myers Squibb Company (BMY) is 1.86%
Based on short-term price targets offered by 21 analysts, the average price target for Bristol Myers Squibb comes to $52.76. The forecasts range from a low of $37.00 to a high of $75.00. The average price target represents a decline of 0.26% from the last closing price of $52.90.